Literature DB >> 29355567

Kuwanon G attenuates atherosclerosis by upregulation of LXRα-ABCA1/ABCG1 and inhibition of NFκB activity in macrophages.

Xiao-Xiao Liu1, Xiao-Wen Zhang2, Kai Wang3, Xue-Ying Wang3, Wen-Long Ma4, Wei Cao5, Dan Mo3, Yang Sun1, Xiao-Qiang Li6.   

Abstract

BACKGROUND: Atherosclerosis is characterized by chronic inflammation in vascular wall. Previous studies suggest that Kuwanon G (KWG) exerts anti-inflammatory activities. However, the effect of KWG on atherosclerosis remains unexplored. AIMS: To explore whether KWG affects macrophage foam cell formation in vitro and atherogenesis in vivo.
METHODS: RAW 264.7 macrophages were stimulated with ox-LDL for 24h to induce foam cell formation and treated with KWG. Foam cell formation was determined by ORO staining and enzymatic analysis. Pro-inflammatory cytokines mRNA levels were tested by Real-time PCR method. Further molecular mechanism was investigated using Western blot. In vivo, ApoE-/- mice were fed with high-fat diet and intraperitoneally injected with KWG. Atherosclerotic lesion was accessed by H&E and ORO staining. Plaque composition was evaluated by immunohistochemistry and Sirius Red staining. Serum lipid profile and inflammatory cytokines were evaluated by enzymatic method and ELISA.
RESULTS: KWG significantly decreased intracellular lipid accumulation and inflammatory cytokines mRNA levels in macrophages through enhancing LXRα-ABCA1/ABCG1 pathway and inhibiting NFκB activation. Administrated with KWG remarkably reduced the atherosclerotic lesion areas and macrophage content in the plaque of high-fat diet fed ApoE-/- mice. KWG also reduced hyperlipidemia and serum inflammatory cytokines in vivo.
CONCLUSION: Taken together, these data highlight that KWG can attenuate atherosclerosis through inhibiting foam cell formation and inflammatory response.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Foam cell formation; Inflammatory; Kuwanon G; Macrophages

Mesh:

Substances:

Year:  2018        PMID: 29355567     DOI: 10.1016/j.taap.2018.01.007

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

1.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

Review 2.  Potential Therapeutic Agents That Target ATP Binding Cassette A1 (ABCA1) Gene Expression.

Authors:  Michael J Haas; Arshag D Mooradian
Journal:  Drugs       Date:  2022-07-21       Impact factor: 11.431

Review 3.  Mulberry Diels-Alder-type adducts: isolation, structure, bioactivity, and synthesis.

Authors:  Si-Yuan Luo; Jun-Yu Zhu; Ming-Feng Zou; Sheng Yin; Gui-Hua Tang
Journal:  Nat Prod Bioprospect       Date:  2022-09-02

Review 4.  Prenylated Flavonoids in Topical Infections and Wound Healing.

Authors:  Alice Sychrová; Gabriela Škovranová; Marie Čulenová; Silvia Bittner Fialová
Journal:  Molecules       Date:  2022-07-13       Impact factor: 4.927

Review 5.  The Signaling Pathways Involved in the Antiatherosclerotic Effects Produced by Chinese Herbal Medicines.

Authors:  Li Lu; Xiaodong Sun; Yating Qin; Xiaomei Guo
Journal:  Biomed Res Int       Date:  2018-06-13       Impact factor: 3.411

6.  CTRP12 ameliorates atherosclerosis by promoting cholesterol efflux and inhibiting inflammatory response via the miR-155-5p/LXRα pathway.

Authors:  Gang Wang; Jiao-Jiao Chen; Wen-Yi Deng; Kun Ren; Shan-Hui Yin; Xiao-Hua Yu
Journal:  Cell Death Dis       Date:  2021-03-10       Impact factor: 8.469

Review 7.  Natural Products Targeting Liver X Receptors or Farnesoid X Receptor.

Authors:  Jianglian She; Tanwei Gu; Xiaoyan Pang; Yonghong Liu; Lan Tang; Xuefeng Zhou
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.